Avidity Biosciences (RNA) Competitors

$13.03 +0.16 (+1.24%)

As of 02:28 PM Eastern

RNA vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Avidity Biosciences compare to Ainos?

Ainos (NASDAQ:AIMDW) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

: In the previous week, Avidity Biosciences had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for Ainos. Ainos' average media sentiment score of 0.00 equaled Avidity Biosciences'average media sentiment score.
Company Overall Sentiment
Ainos Neutral
Avidity Biosciences Neutral
: Avidity Biosciences has a consensus price target of $69.42, indicating a potential upside of 432.78%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Ainos.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ainos
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Avidity Biosciences
1 Sell rating(s)

12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
: Ainos has higher earnings, but lower revenue than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ainos $124.16K N/A N/A N/A N/A
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A
: Ainos has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Ainos' return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Ainos N/A N/A N/A
Avidity Biosciences -3,650.39% -44.92% -39.57%

Company	Overall Sentiment
Ainos	Neutral
Avidity Biosciences	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$124.16K	N/A	N/A	N/A	N/A
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	N/A	N/A
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Summary

Avidity Biosciences beats Ainos on 6 of the 9 factors compared between the two stocks.

How does Avidity Biosciences compare to Alvotech?

Avidity Biosciences (NASDAQ:RNA) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

: Avidity Biosciences presently has a consensus price target of $69.42, indicating a potential upside of 432.78%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Alvotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
Alvotech
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Alvotech has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Alvotech's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Avidity Biosciences -3,650.39% -44.92% -39.57%
Alvotech N/A N/A N/A
: In the previous week, Avidity Biosciences had 1 more articles in the media than Alvotech. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for Alvotech. Avidity Biosciences' average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score.
Company Overall Sentiment
Avidity Biosciences Neutral
Alvotech Neutral
: Alvotech has higher revenue and earnings than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A
Alvotech $586.32M N/A N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
Alvotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Alvotech	N/A	N/A	N/A

Company	Overall Sentiment
Avidity Biosciences	Neutral
Alvotech	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A
Alvotech	$586.32M	N/A	N/A	N/A	N/A

Summary

Avidity Biosciences beats Alvotech on 5 of the 9 factors compared between the two stocks.

How does Avidity Biosciences compare to Aravive?

Aravive (NASDAQ:ARAV) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

: Avidity Biosciences has a consensus price target of $69.42, indicating a potential upside of 432.78%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Aravive.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aravive
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Avidity Biosciences
1 Sell rating(s)

12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
: Aravive has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Aravive's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Aravive N/A N/A N/A
Avidity Biosciences -3,650.39% -44.92% -39.57%
: Aravive has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
: In the previous week, Avidity Biosciences had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for Aravive. Aravive's average media sentiment score of 0.00 equaled Avidity Biosciences'average media sentiment score.
Company Overall Sentiment
Aravive Neutral
Avidity Biosciences Neutral
: 35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Aravive has higher earnings, but lower revenue than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aravive $6.99M 0.42 -$66.21M -$0.90 N/A
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Company	Overall Sentiment
Aravive	Neutral
Avidity Biosciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	$6.99M	0.42	-$66.21M	-$0.90	N/A
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A

Summary

Aravive beats Avidity Biosciences on 8 of the 14 factors compared between the two stocks.

How does Avidity Biosciences compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Avidity Biosciences (NASDAQ:RNA) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

: Atlantic Coastal Acquisition Corp. II has higher earnings, but lower revenue than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A
: Avidity Biosciences has a consensus price target of $69.42, indicating a potential upside of 432.78%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Atlantic Coastal Acquisition Corp. II.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atlantic Coastal Acquisition Corp. II
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Avidity Biosciences
1 Sell rating(s)

12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
: Atlantic Coastal Acquisition Corp. II has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Atlantic Coastal Acquisition Corp. II's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. II N/A N/A N/A
Avidity Biosciences -3,650.39% -44.92% -39.57%
: In the previous week, Avidity Biosciences had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for Atlantic Coastal Acquisition Corp. II. Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Avidity Biosciences'average media sentiment score.
Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Avidity Biosciences Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atlantic Coastal Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Company	Net Margins	Return on Equity	Return on Assets
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Company	Overall Sentiment
Atlantic Coastal Acquisition Corp. II	Neutral
Avidity Biosciences	Neutral

Summary

Avidity Biosciences beats Atlantic Coastal Acquisition Corp. II on 6 of the 9 factors compared between the two stocks.

How does Avidity Biosciences compare to Biofrontera?

Avidity Biosciences (NASDAQ:RNA) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

: Biofrontera has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Biofrontera's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Avidity Biosciences -3,650.39% -44.92% -39.57%
Biofrontera N/A N/A N/A
: Avidity Biosciences presently has a consensus price target of $69.42, indicating a potential upside of 432.78%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Biofrontera.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
Biofrontera
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Avidity Biosciences and Avidity Biosciences both had 1 articles in the media. Avidity Biosciences' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.
Company Overall Sentiment
Avidity Biosciences Neutral
Biofrontera Neutral
: Biofrontera has higher revenue and earnings than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A
Biofrontera $41.71M N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Biofrontera	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
Biofrontera	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Avidity Biosciences	Neutral
Biofrontera	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A
Biofrontera	$41.71M	N/A	N/A	N/A	N/A

Summary

Avidity Biosciences and Biofrontera tied by winning 4 of the 8 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNA vs. The Competition

Export

Metric	Avidity Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$3.38B	$6.24B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-2.62	38.92	29.06	28.45
Price / Sales	N/A	158.54	475.43	61.47
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	1.20	6.99	9.69	6.64
Net Income	-$322.30M	$23.62M	$3.55B	$332.53M
7 Day Performance	3.82%	3.06%	1.46%	1.83%
1 Month Performance	-3.05%	6.56%	5.35%	8.98%
1 Year Performance	-59.63%	65.81%	33.88%	39.30%

Avidity Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNA Avidity Biosciences	1.3252 of 5 stars	$13.03 +1.2%	$69.42 +432.8%	N/A	$0.00	$18.62M	N/A	190
AIMDW Ainos	N/A	$0.05 -35.8%	N/A	N/A	$0.00	$124.16K	N/A	40	Positive News
ALVOW Alvotech	N/A	$0.26 +21.3%	N/A	N/A	$0.00	$586.32M	N/A	4	Positive News Upcoming Earnings Gap Up High Trading Volume
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Competitors

RNA vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

How does Avidity Biosciences compare to Ainos?

Summary

How does Avidity Biosciences compare to Alvotech?

Summary

How does Avidity Biosciences compare to Aravive?

Summary

How does Avidity Biosciences compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does Avidity Biosciences compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Competitors

RNA vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

How does Avidity Biosciences compare to Ainos?

Summary

How does Avidity Biosciences compare to Alvotech?

Summary

How does Avidity Biosciences compare to Aravive?

Summary

How does Avidity Biosciences compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does Avidity Biosciences compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools